Literature DB >> 26876316

Treatment of Bipolar Depression: Evolving Recommendations.

Robert M Post1.   

Abstract

Bipolar depression is the most common and difficult-to-treat phase of bipolar disorder. Antidepressants for unipolar depression are among the most widely used drugs, but recent data and meta-analyses indicate a lack of efficacy. Many of the drugs discussed here are graded provisionally for the strength of the findings in the literature, safety and tolerability, and likely utility of use in patients with bipolar disorder. Successful long-term treatment of bipolar depression is critical to preventing illness-related morbidity, disability, cognitive decline, suicide, and premature loss of years of life expectancy largely from the excess medical mortality associated with cardiovascular disorders.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticonvulsants; Anxiety; Atypical antipsychotics; Lithium; Neurotrophic factors; Psychoeducation; Rapid cycling; Substance abuse

Mesh:

Substances:

Year:  2016        PMID: 26876316     DOI: 10.1016/j.psc.2015.09.001

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  10 in total

1.  The Kindling/Sensitization Model and Early Life Stress.

Authors:  Robert M Post
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 2.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

Review 3.  Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews.

Authors:  Michele Fornaro; Domenico De Berardis; Giampaolo Perna; Marco Solmi; Nicola Veronese; Laura Orsolini; Elisabetta Filomena Buonaguro; Felice Iasevoli; Cristiano André Köhler; André Ferrer Carvalho; Andrea de Bartolomeis
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

4.  Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial.

Authors:  Lakshmi N Yatham; Eduard Vieta; Willie Earley
Journal:  Int Clin Psychopharmacol       Date:  2020-05       Impact factor: 1.659

5.  Emotional regulation neural circuitry abnormalities in adult bipolar disorder: dissociating effects of long-term depression history from relationships with present symptoms.

Authors:  Michele A Bertocci; Jeffrey Bergman; Joao Paulo Lima Santos; Satish Iyengar; Lisa Bonar; Mary Kay Gill; Halimah Abdul-Waalee; Genna Bebko; Richelle Stiffler; Jeanette Lockovich; Haris Aslam; Cecile Ladouceur; John Merranko; Rasim Diler; Boris Birmaher; Amelia Versace; Mary L Phillips
Journal:  Transl Psychiatry       Date:  2020-11-02       Impact factor: 6.222

Review 6.  Possible Antidepressant Effects of Memantine-Systematic Review with a Case Study.

Authors:  Marek Krzystanek; Stanisław Surma; Artur Pałasz; Monika Romańczyk; Krzysztof Krysta
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-18

7.  Functional Implications of the CLOCK 3111T/C Single-Nucleotide Polymorphism.

Authors:  Angela R Ozburn; Kush Purohit; Puja K Parekh; Gabrielle N Kaplan; Edgardo Falcon; Shibani Mukherjee; Hannah M Cates; Colleen A McClung
Journal:  Front Psychiatry       Date:  2016-04-21       Impact factor: 4.157

Review 8.  The New News about Lithium: An Underutilized Treatment in the United States.

Authors:  Robert M Post
Journal:  Neuropsychopharmacology       Date:  2017-10-04       Impact factor: 7.853

Review 9.  Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data.

Authors:  Robert M Post; Benjamin I Goldstein; Boris Birmaher; Robert L Findling; Benicio N Frey; Melissa P DelBello; David J Miklowitz
Journal:  J Affect Disord       Date:  2020-03-06       Impact factor: 4.839

Review 10.  Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management.

Authors:  Robert M Post; Lakshmi N Yatham; Eduard Vieta; Michael Berk; Andrew A Nierenberg
Journal:  Bipolar Disord       Date:  2019-08-19       Impact factor: 5.345

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.